 Luminex Corporation NASDAQ: LMNX today announced that the company has delivered the first of its new xMAP INTELLIFLEX Systems to several of its Life Science Research Partners, achieving a major milestone in the companys strategy to extend its xMAP Technology with new functionality to facilitate new applications. Initially intended for research use only, the new system can double the multiplex capabilities of the xMAP platform, enabling partners and customers to explore new applications. Included in these applications is the unique ability to use a dual-reporter to simultaneously detect multiple COVID-19 antibodies in a single serology test. 